VIDA IS ACCELERATING

RESPIRATORY CLINICAL TRIALS

THROUGH INTELLIGENCE

COVID-19

Asthma

COPD

ILD

Cancer

Emphysema

Respiratory clinical trials are costly and inefficient,
Our mission is to accelerate therapies to patients.

$985M average R&D costs for novel therapeutics58% of respiratory drugs fail at the final phase of trials1 of every 7 adults suffers from a lung disorderLung is the #1 most expensive clinical trial disease category

Lung Intelligence enables data-driven clinical trials, empowering efficiencies through precision endpoints, optimized imaging operations, and data insights.

0+
Sites
0+
Countries
0+TB
Lung Data
0+
Metrics per Study